Baird analyst Jack Allen raised the firm’s price target on Taysha Gene Therapies (TSHA) to $12 from $7 and keeps an Outperform rating on the shares, telling investors that the firm is “encouraged” that Taysha reached alignment with the FDA on the 15-patient pivotal study of TSHA-102 in Rett syndrome. The FDA having granted TSHA-102 breakthrough therapy designation is “another encouraging sign,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Berkshire to acquire OxyChem, OpenAI reaches $500B valuation: Morning Buzz
- Promising Prospects for Taysha Gene Therapies: Buy Rating Backed by Strategic Advancements and Regulatory Endorsements
- Needham ups Taysha target on ‘derisking’ TSHA-102 news
- Taysha Gene Therapies price target raised to $10 from $8 at Needham
- Positive Outlook for Taysha Gene Therapies: Buy Rating Affirmed with FDA Support and Breakthrough Designation